Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 3Lymphoid 2Dermatologic 2Tumor-Agnostic 1Sarcoma 1Other neoplasm 1Other hematologic neoplasm 1Myeloid 1Classical hematology 1Breast 1

Conditions

Precancerous Conditions 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Keratosis, Actinic 1Dermatitis, Contact 1Carcinoma, Basal Cell 1

Interventions

pembrolizumab 339Nivolumab 305Ipilimumab 274Cyclophosphamide 195aldesleukin 148Interleukin-2 110fludarabine phosphate 107trametinib 85Temozolomide 83fludarabine 81Dacarbazine 81dabrafenib 77Radiotherapy 75Biopsy 75Vemurafenib 71Imiquimod 53Bevacizumab 51sargramostim 50Magnetic Resonance Spectroscopy 50Specimen Handling 49Radiosurgery 49Peripheral Blood Stem Cell Transplantation 49Paclitaxel 49Aminolevulinic Acid 49binimetinib 48Carboplatin 48Blood Specimen Collection 47cemiplimab 46Cisplatin 453-ingenyl angelate 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Triamcinolone × Dermatologic × Clear all
NCT03380026 2021-11-24

MIDAS

Rochester Skin Lymphoma Medical Group, PLLC

Phase 2 Completed
28 enrolled 8 charts
DermatologicLymphoid

Dermatitis, Contact, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous

NCT00021294 2018-09-11

Eflornithine With or Without Triamcinolone in Preventing Nonmelanoma Skin Cancer in Patients With Actinic Keratosis

University of Arizona

Phase 2 Completed
DermatologicOther neoplasm

Carcinoma, Basal Cell, Precancerous Conditions, Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡